Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Colitis, Ulcerative, Inflammatory Bowel Diseases
Interventions: Placebo IV, Placebo SC, Ustekinumab IV, Ustekinumab SC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 68
States / cities: Birmingham, Alabama • La Mirada, California • Los Angeles, California + 65 more

Conditions: Cradle Cap, Infantile Seborrheic Dermatitis
Interventions: Promiseb Topical Cream, Bland emollient; Device · Other
Lead sponsor: Promius Pharma, LLC; Industry
Eligibility: 30 Days and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Norwich, Connecticut • Louisville, Kentucky • Newark, New Jersey + 1 more

Conditions: Type 2 Diabetes Mellitus
Interventions: LAF 237; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: Taselisib, Placebo, Fulvestrant; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 16
States / cities: Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more

Conditions: Pain
Interventions: bupivicaine epidural, bupivicaine epidural infusion patient epidural, bupivicaine; Drug
Lead sponsor: MemorialCare; Other
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Long Beach, California

Conditions: TQT Study
Interventions: Tetrodotoxin, Placebos; Drug
Lead sponsor: Wex Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Liver Disease; Alcohol-Related, Cirrhosis, Alcohol Use Disorder
Interventions: Intestinal Microbiota Transplant (IMT) Capsules, Placebo Capsules; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Richmond, Virginia

Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions: PF-04991532, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Chula Vista, California • Fountain Valley, California • Miami, Florida + 1 more

Conditions: Asthma
Interventions: Montelukast 10 mg orally, Placebo; Drug · Other
Lead sponsor: Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.; Other
Eligibility: 65 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Fingolimod, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,083 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 100
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 86 more

Conditions: Posttraumatic Stress Disorder, Substance Dependence
Interventions: Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS), Cognitive-Behavioral Therapy for Substance Dependence; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Migraine
Interventions: Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 38
States / cities: San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more

Conditions: COVID-19
Interventions: vitamin D, Placebo; Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2,024 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Opioid Use Disorder
Interventions: Morphine, AZD4041, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Asthma
Interventions: MN-221, Placebo; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 4
States / cities: Lenexa, Kansas • North Dartmouth, Massachusetts • Rolla, Missouri + 1 more

Conditions: Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Interventions: JK07, Placebo; Drug
Lead sponsor: Salubris Biotherapeutics Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 51
States / cities: Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 45 more

Conditions: Atrial Fibrillation, Stroke
Interventions: Computer Electronic Alert; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Interstitial Lung Disease
Interventions: efzofitimod 450 mg, efzofitimod 270 mg, Placebo; Drug
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 10 more

Conditions: Bipolar I Disorder, Depression, Anxiety, Stress
Interventions: Magnesium vitamin B6, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Parkinson's Disease
Interventions: MEDI1341, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Long Beach, California • Hallandale, Florida • Atlanta, Georgia + 2 more

Conditions: Diabetic Macular Edema
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 48
States / cities: La Jolla, California • Redlands, California • Santa Maria, California + 44 more

Conditions: Wound Heal, Diabetic Foot Ulcer
Interventions: EDX110; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Phoenix, Arizona • Los Angeles, California • Santa Ana, California + 6 more

Conditions: Healthy
Interventions: TT-00920, TT-00920 Placebo; Drug
Lead sponsor: TransThera Sciences (Nanjing), Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Clopidogrel, Placebo, Omeprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Promiseb Topical Cream for Cradle Cap

Acute Metabolic Effects of LAF 237 in Type 2 Diabetics

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Patient Controlled Epidural Analgesia Versus Continuous Epidural Infusion: Obstetrical and Neonatal Outcomes

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects

Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease

Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes

Asthma in the Elderly: The Effect of Montelukast

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Trial of a Novel Cognitive-Behavioral Treatment for Posttraumatic Stress and Substance Dependence

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

Vitamin D for COVID-19 Trial

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

Study of JK07 in Patients With Chronic Heart Failure

Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Efficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder

Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

EDX110 Randomized Control Trial for Treatment of DFUs

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy Subjects

Interaction Study of Clopidogrel 600/150 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects